


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449A/PTO <div style="text-align: center;">  <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p> </div>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;">09/709,045</td> </tr> <tr> <td>Filing Date</td> <td>November 10, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>M. Rigdon Lentz</td> </tr> <tr> <td>Group Art Unit</td> <td>1647</td> </tr> <tr> <td>Examiner Name</td> <td>Lorraine Spector</td> </tr> <tr> <td>Attorney Docket Number</td> <td>LEN 102</td> </tr> </table>		Application Number	09/709,045	Filing Date	November 10, 2006	First Named Inventor	M. Rigdon Lentz	Group Art Unit	1647	Examiner Name	Lorraine Spector	Attorney Docket Number	LEN 102
Application Number	09/709,045														
Filing Date	November 10, 2006														
First Named Inventor	M. Rigdon Lentz														
Group Art Unit	1647														
Examiner Name	Lorraine Spector														
Attorney Docket Number	LEN 102														

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code* (if known)			
		4,439,332		Frank	03-27-1984	
		4,708,713		Lentz	11-24-1987	
		4,863,611		Bernstein	09-05-1989	
		5,135,919		Folkman et al.	08-04-1992	
		5,147,638		Esmon, et al.	09-15-1992	
		5,290,807		Folkman, et al.	03-01-1994	
		5,610,279		Brockhaus	03-11-1997	
		5,629,327		D'Amato	05-13-1997	
		5,639,725		O'Reilly, et al.	06-17-1997	
		5,698,586		Kishimoto, et al.	12-16-1997	
		5,712,291		D'Amato	01-27-1998	
		5,713,491		Hughes, et al.	02-03-1998	
		5,716,981		Hunter, et al.	02-10-1998	
		5,733,876		O'Reilly et al.	03-31-1998	

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/709,045
		Filing Date	November 10, 2006
		First Named Inventor	M. Rigdon Lentz
		Group Art Unit	1647
		Examiner Name	Lorraine Spector
Sheet	2	of	8
		Attorney Docket Number	LEN 102

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		5,712,291		D'Amato	06-27-1998	
		5,808,029		Brockhaus	09-15-1998	
		5,817,522		Goodman, et al.	10-06-1998	
		6,133,431		Yusada	10-17-2000	
		6,379,708		Howell, et al.	04-30-2002	
		2005-0244371		Lentz	06-14-2005	
		2005-0265996		Lentz	10-26-2000	
		09/709,045		Lentz	11-10-2000	
		09/699,003		Lentz	10-26-2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† <sup>3</sup>
		Office. <sup>2</sup>	Number <sup>2</sup>	Kind Code <sup>2</sup> (if known)				
		PCT	WO 99/61085 A		Lentz	12-02-1999		
				</				

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/APTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/709,045
				Filing Date	November 10, 2006
				First Named Inventor	M. Rigdon Lentz
				Group Art Unit	1647
				Examiner Name	Lorraine Spector
Sheet	3	of	8	Attorney Docket Number	LEN 102

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T‡
		AGISHI, Anion-blood contact (ABC reaction) in patients treated by LDL apheresis with dextran sulfate-cellulose column while receiving ACE inhibitors (letter). JAMA; 271:195-6(1994).	
		ANDREWS, et al., "Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin LT) on human T lymphocytes: TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma," <i>J Immunol</i> 144:2582-2591 (1990).	
		BANYAI et al., "Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoapheresis," <i>Metabolism</i> 47(9):1058-1064 (1998).	
		BONAVIDA, et al., (eds), Tumor Necrosis Factor/Cachectin and Related Cytokines. Int. Conf. Tumor Necrosis Factor and Related Cytotoxins, Heidelberg, 1987, pp. 7-19 (Karger, Basel 1988).	
		CHEN, et al., "Soluble TNF-α Receptors are constitutively shed and downregulate adhesion molecule expression in malignant gliomas," <i>J. Neuropathol. Exp. Neurol.</i> 56(5):541-550 (1997).	
		CLACKSON, et al., "Making of antibody fragments using phage display libraries," <i>Nature</i> 352: 624-688 (1991).	
		COLMAN, et al., <i>Hemostasis and Thrombosis: Basic Principles and Clinical Practice 2nd. Edition</i> (Colman, et al., eds.) pp. 242-267 J.B. Lippincott: Philadelphia, PA, 1987.	
		CYTOLOGIC, "Unleash Immunotherapy," CytoLogic non CDA info.doc., pp. 1-10 (April 27, 2006).	
		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19: 2471-2476 (1991).	
		EY, et al., "Isolation of pure IgG1, IgG2a, and IgG2b immunoglobins from mouse serum using protein A-Sepharose," <i>Immunochemistry</i> 15:429-436 (1978).	
		FEINMAN, et al., "Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes," <i>J Immunol</i> 138:635 (1987).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

† Unique citation designation number ‡ See attached Kinds of U.S. Patent Documents. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*\* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*\*\* Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/709,045
		Filing Date	November 10, 2006
		First Named Inventor	M. Rigdon Lentz
		Group Art Unit	1647
		Examiner Name	Lorraine Spector
		Attorney Docket Number	LEN 102
Sheet	4	of	8

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		GATANAGA, et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients," <i>Proceedings of the National Academy of the USA</i> 87(22):8781-8784 (1990).	
		GATANAGA, et al., "Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients," <i>Lymphokine Res</i> 9:225-9 (1990).	
		<del>GUYTON and HALL, <i>Textbook of Medical Physiology</i> 9<sup>th</sup> ed. Pp. 290</del>	
		HARANAKA, et al., "Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro," <i>Jpn J Exp Med</i> 51:191 (1981).	
		HARLOW et al., <i>Antibodies, A Laboratory Manual</i> , Chapter 13, "Immunoaffinity Purification," pp. 511-552, 1988	
		<i>Hemostasis and Thrombosis: Basic Principles and Clinical Practice</i> 2nd Ed., Colman, R.W., et al., p. 263 (J.B. Lippincott, Philadelphia, PA 1987),	
		HONG et al., "Intercellular adhesion molecule-1 expression induced by interleukin (IL)-1 beta or an IL-1 beta fragment is blocked by an IL-1 receptor antagonist and a soluble IL-1 receptor," <i>Journal of Neuroimmunology</i> , 44(2):163-170 (1993).	
		HOWARD, et al., Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family," <i>Virology</i> 180(2):633-47 (1991).	
		IBM Technical Disclosure Bulletin, Vol 19, No 3. August 1976 pp. 765-768	
		JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," <i>Arch Immunol Ther Exp (Warsz)</i> . 45(5-6):449-53 (1997).	
		<del>JANEWAY, et al. <i>Immunobiology. The Immune System in Health and Disease</i>, 4<sup>th</sup> Ed. Pp. 102</del>	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/709,045
				Filing Date	November 10, 2006
				First Named Inventor	M. Rigdon Lentz
				Group Art Unit	1647
				Examiner Name	Lorraine Spector
Sheet	5	of	8	Attorney Docket Number	LEN 102

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		KABAT, et al., <u>Sequences of Proteins of Immunological Interest</u> 4 <sup>th</sup> Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987).	
		KAMINSKA, et al., "Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I—an independent prognostic factor," <i>Tumour Biol.</i> 26(4):186-94(2005).	
		KAMINSKA, et al., "Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor," <i>Oncology</i> 70(2):115-25(2006).	
		KOJIMA, et al., "Effect of nafamostat mesilate on bradykinin generation during lowdensity lipoprotein apheresis using a dextran sulfate cellulose column," <i>ASAIO Trans</i> 37: 644-8(1991).	
		LANGKOPF, et al., "Soluble tumor necrosis factor receptors as prognostic factors in cancer patients," <i>Lancet</i> 344:57-58 (1994).	
		LENTZ, "Continuous whole blood UltraPheresis procedure in patients with metastatic cancer," <i>Journal of Biological Response Modifiers</i> 8(5):511-527 (1989).	
		LENTZ, "The role of therapeutic apheresis in the treatment of cancer: a review," <i>Therapeutic Apheresis</i> 3(1):40-49 (1999).	
		MARUYAMA, et al., "Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering," <i>Cell</i> 48(2):343-350(1987).	
		MATHIAS, et al., "Activation of the Spingomyelin signaling pathway intact EL4 cells and in a cell-free system by IL-1b," <i>Science</i> 259:519-522 (1993).	
		MATSCHINER, et al., <u>Current Advances in Vitamin K Research</u> , pp. 135-140, John W. Suttie, ed. (Elsevier Science Publishing Co., Inc. 1988)	
		MITTEREGGER, et al., "In vitro cell culture systems as the basis for an extracorporeal blood purification strategy in multiorgan failure treatment", <i>Ther Apher.</i> , 3(3):257-63 (1999).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/APTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/709,045
		Filing Date	November 10, 2006
		First Named Inventor	M. Rigdon Lentz
		Group Art Unit	1647
		Examiner Name	Lorraine Spector
		Attorney Docket Number	LEN 102
Sheet	6	of	8

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		NATIONAL CANCER INSTITUTE, "Biological Therapies for Cancer: Questions and Answers," National Cancer Institute FactSheet (08-16-2004).	
		OLD, Antitumor activity of microbial products and tumor necrosis factor, and Bonavida B, et al., (eds): Tumor Necrosis Factor/Cachecins and Related Cytokines, Basel, Karger, p7 (1988).	
		PALASZYNSKI, "Synthetic C-terminal peptide of IL-1 functions as a binding domain as well as an antagonist for the IL-1 receptor," <i>Biochemical and Biophysical Research Communications</i> , 147(1):204-211(1987).	
		PENNICA et al., "Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor-alpha induced receptor aggregation," <i>Biochemistry</i> 31(4):1134-1141(1992).	
		PENNICA et al., "Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor," <i>Biochemistry</i> 32(12): 3131-3138(1993).	
		PHILIP & EPSTEIN, "Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, Gamma-interferon and Interleukin-1," <i>Nature</i> 323(6083):86-87 (1986).	
		Product description: catalog number AB-225-PB catalog of R&D Systems. (1994).	
		Product description: catalog number AB-226-PB catalog of R&D Systems (1994).	
		Product description: catalog numbers FAB225F catalog of R&D Systems (1998).	
		Product description: catalog numbers MAB225 catalog of R&D Systems (1998).	
		Product description: catalog numbers AF-425-PB catalog of R&D Systems (1998).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/APTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/709,045
				Filing Date	November 10, 2006
				First Named Inventor	M. Rigdon Lentz
				Group Art Unit	1647
				Examiner Name	Lorraine Spector
Sheet	7	of	8	Attorney Docket Number	LEN 102

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	F <sup>2</sup>
		<del>Product description of antibody AHR0042. Disclosure catalog</del>	
		SELINSKY, et al., "Multifaceted inhibition of anti-tumor immune mechanisms by soluble tumour necrosis factor receptor type-1," <i>Immunology</i> 94(1):88-93 (1998).	
		SHIBATA, et al., "Changes of cell-mediated immunity with an advance of cancer-relation to the th1/th2 balance and inhibitors of th1 cytokines," <i>Biotherapy</i> , 12(5):715-17 (1998).	
		SIDHU AND BOLLON, "Tumor necrosis factor activities and cancer therapy - A perspective" <i>Pharmacol. Ther.</i> 57:79-128 (1993).	
		TETTA, et al., "Continuous plasma filtration coupled with sorbents," <i>Kidney International</i> 53(66):S186-S189 (1998).	
		URBAN, et al., "Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages," <i>Proc Natl Acad Sci USA</i> 83:5233-37 (1986).	
		VAN ZEE, et al., "Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha <i>in vitro</i> and <i>in vivo</i> " <i>PNAS</i> 89:4845-4849 (1992).	
		VERMA et al., "Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems," <i>Journal of Immunological Methods</i> , 216(1-2):165-181(1998).	
		WARZOSHA, et al. "Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients," <i>J Clin Oncol.</i> 15(2):499-508(1997).	
		WINTER, et al. "Synthetic human antibodies and a strategy for protein engineering," <i>FEBS Letters</i> , 430:92-94(1998).	
		YAMAZAKI et al. Biocompatibility of plasma separator of an improved cellulose acetate hollow fiber. In: Sieberth HG (ed). Plasma Exchange. New York: fk Schattauer, 45-51(1980).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number		09/709,045	
				Filing Date		November 10, 2006	
				First Named Inventor		M. Rigdon Lentz	
				Group Art Unit		1647	
				Examiner Name		Lorraine Spector	
Sheet		8		of		8	
				Attorney Docket Number		LEN 102	

[illegible]

Examiner's Signature	/Cherie M. Woodward/	Date Considered	11/08/2011
----------------------	----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/